Kamada (KMDA) Income from Non-Controlling Interests (2019 - 2022)
Kamada's (KMDA) quarterly Income from Non-Controlling Interests came in at -$108000.0 in Q1 2022, down 47.95% YoY from -$207473.7 in Q1 2021, and down 47.95% on a QoQ basis from -$73000.0 in Q1 2021.
Kamada (KMDA) Income from Non-Controlling Interests (2019 - 2022) Analysis & Trends
Kamada (KMDA) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$108000.0 in Q1 2022.
- Quarterly Income from Non-Controlling Interests fell 47.95% year-over-year to -$108000.0 in Q1 2022, while the trailing twelve-month figure through Mar 2022 was $134000.0 (changed N/A YoY) and the FY2021 annual result came in at $185000.0, down 78.88% from the prior year.
- Income from Non-Controlling Interests eased to -$108000.0 in Q1 2022, from -$73000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $241000.0 in Q1 2020 to a low of -$108000.0 in Q1 2022.
- A 4-year average of $33500.0 and a median of $500.0 in 2019 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2020 — Income from Non-Controlling Interests soared 225.68% — and 2021, when it sank 130.29%.
- Tracing KMDA's Income from Non-Controlling Interests over 4 years: stood at $74000.0 in 2019, then soared by 225.68% to $241000.0 in 2020, then slumped by 130.29% to -$73000.0 in 2021, then plunged by 47.95% to -$108000.0 in 2022.
- The last three Income from Non-Controlling Interests figures came in at -$108000.0 (Q1 2022), -$73000.0 (Q1 2021), and $241000.0 (Q1 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Kamada | 462.32 Mn | 432.85 Mn | 22.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -108,000.00 |
| Mar 31, 2021 | -73,000.00 |
| Mar 31, 2020 | 241,000.00 |
| Mar 31, 2019 | 74,000.00 |